Hematology focuses on diseases of the blood, bone marrow, and lymphatic system. Learn about the diagnosis and treatment of anemia, leukemia, and lymphoma.
Send us all your questions or requests, and our expert team will assist you.
Polycythemia Vera is a chronic, progressive myeloproliferative neoplasm characterized by the unregulated proliferation of the erythroid, megakaryocytic, and granulocytic lineages in the bone marrow. While the disease is clinically defined by an absolute increase in red blood cell mass, it is biologically a panmyelosis, meaning that it involves the overproduction of red blood cells, white blood cells, and platelets. Under normal physiological conditions, the production of red blood cells, a process known as erythropoiesis, is strictly controlled by a negative feedback loop involving tissue oxygenation and the hormone erythropoietin. In
Polycythemia Vera, this regulatory mechanism is bypassed due to acquired somatic mutations in the hematopoietic stem cells. The resulting overproduction of cellular components leads to hyperviscosity, or thickening of the blood, which significantly impairs microcirculatory flow and predisposes patients to both thrombotic and hemorrhagic complications. At Liv Hospital, we approach Polycythemia Vera not merely as a condition of high blood counts, but as a systemic malignancy requiring a nuanced understanding of molecular genetics and vascular biology for effective long term management.
To understand the pathology of Polycythemia Vera, one must first comprehend the sophisticated machinery of normal blood production.
Erythropoietin is a glycoprotein hormone produced primarily by the peritubular interstitial cells of the kidney. Its production is inversely related to tissue oxygen tension. When oxygen levels in the kidney drop (hypoxia), erythropoietin synthesis increases. This hormone travels to the bone marrow, where it binds to receptors on erythroid progenitor cells, preventing their apoptosis and stimulating their differentiation into mature red blood cells.
The transmission of the erythropoietin signal from the cell surface to the nucleus relies on the Janus Kinase (JAK) and Signal Transducer and Activator of Transcription (STAT) pathway. When erythropoietin binds to its receptor, JAK2 molecules attached to the receptor are activated. These JAK2 molecules phosphorylate STAT proteins, which then dimerize and move into the nucleus to activate genes responsible for cell survival and proliferation. In a healthy individual, this system turns off once oxygen levels are restored.
Polycythemia Vera is distinct among blood cancers because its genetic driver is identified in nearly all cases.
This somatic mutation is found in approximately 95 to 98 percent of patients with Polycythemia Vera. It involves a single nucleotide substitution (guanine to thymidine) at position 1849 in exon 14 of the JAK2 gene. This change results in the substitution of valine for phenylalanine at codon 617 in the JAK2 protein.
This structural change renders the kinase domain of the protein permanently active. Consequently, the signaling pathway remains switched on even in the absence of erythropoietin. The hematopoietic cells behave as if they are constantly being stimulated to grow, leading to unchecked proliferation. This phenomenon allows the malignant clone to outcompete normal stem cells, eventually dominating the bone marrow.
In the small minority of patients who lack the V617F mutation, deletions or substitutions in exon 12 of the JAK2 gene are typically found. These mutations result in a similar gain of function but are often associated with isolated erythrocytosis (high red cells only) rather than the panmyelosis seen in V617F positive cases.
The clinical dangers of Polycythemia Vera are largely physical, stemming from the altered fluid dynamics of the blood.
Blood viscosity increases exponentially as the hematocrit rises above 45 percent. In Polycythemia Vera, hematocrit levels can exceed 60 percent if untreated. This transforms the blood from a free flowing fluid into a sludge like substance.
This thickened blood moves sluggishly through the microvasculature, the tiny capillaries responsible for delivering oxygen to tissues. This stagnation leads to tissue hypoxia, which paradoxically can stimulate even more blood vessel growth, though the primary issue is flow, not vessel density.
In normal blood flow, red blood cells travel in the center of the vessel (axial stream), while platelets flow near the vessel wall (marginal zone). The massive expansion of the red cell mass in Polycythemia Vera displaces platelets closer to the endothelium, increasing the likelihood of platelet vessel wall interaction and subsequent thrombosis.
Polycythemia Vera is a dynamic disease that evolves through recognizable stages over decades.
This prodromal stage is characterized by mild or borderline erythrocytosis. Patients may be asymptomatic, and the condition is often misdiagnosed or attributed to lifestyle factors. The red cell mass may not yet meet the diagnostic threshold, but the JAK2 mutation is present.
This is the classic presentation of the disease. Red cell mass is significantly increased, often accompanied by leukocytosis (high white cells) and thrombocytosis (high platelets). The risk of thrombosis is highest during this phase, and patients typically present with symptoms of hyperviscosity.
Over time, the chronic hyperactivity of the bone marrow creates a toxic environment rich in inflammatory cytokines. This eventually leads to the deposition of reticulin and collagen fibers, scarring the marrow. As fibrosis advances, the marrow fails, and blood cell production drops. The spleen enlarges massively to compensate (extramedullary hematopoiesis), and the patient transitions from having too much blood to becoming anemic.
Polycythemia Vera is considered a rare disease, or orphan disease, but it is the most common of the Philadelphia chromosome negative myeloproliferative neoplasms.
It is primarily a disease of older adulthood, with a median age at diagnosis of approximately 60 years. While rare, it can occur in young adults and exceptionally in children. Men are affected slightly more frequently than women.
The annual incidence is estimated to be around 0.8 to 2.8 cases per 100,000 persons. Prevalence rates are higher, reflecting the chronic nature of the disease and the prolonged survival of well managed patients.
Send us all your questions or requests, and our expert team will assist you.
Primary polycythemia (Polycythemia Vera) is caused by a genetic mutation in the bone marrow itself. Secondary polycythemia is caused by external factors like smoking, lung disease, or high altitude that force a normal bone marrow to produce more red cells.
Generally, no. The JAK2 mutation is a somatic mutation, meaning it is acquired during your lifetime in a single stem cell. It is not usually present in the sperm or egg, so it is rarely passed down to children.
Thick blood flows slowly, making it harder for the heart to pump and easier for clots to form. This can block blood flow to vital organs like the brain, heart, and lungs.
With proper monitoring and treatment, the life expectancy for many patients approaches that of the general population. The major risks to life are preventable complications like clots, rather than the cancer itself.
While it is a cancer of blood cells, it does not typically cause immune deficiency. In fact, it often causes high white blood cell counts, which can lead to a state of chronic inflammation.
Your Comparison List (you must select at least 2 packages)
